Literature DB >> 23769207

Treatment and detection of ALK-rearranged NSCLC.

Solange Peters1, Miquel Taron, Lukas Bubendorf, Fiona Blackhall, Rolf Stahel.   

Abstract

The recent approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC) in the US and other countries has provoked intense interest in ALK rearrangements as oncogenic drivers, and promises to revolutionise the way in which NSCLC is diagnosed and treated. Here, we review clinical data to date for the use of crizotinib to treat patients with advanced, ALK-positive NSCLC and consider issues surrounding the detection of ALK-positivity including the use of fluorescence in situ hybridisation and the other potential techniques available, and their suitability for ALK screening. We also discuss the emergence of resistance to crizotinib therapy and the range of other ALK inhibitors currently in development.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ALK inhibitor; ALK rearrangement; Crizotinib; Diagnosis; NSCLC; Resistance

Mesh：

Substances：

Year:  2013        PMID： 23769207     DOI： 10.1016/j.lungcan.2013.03.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  9 in total

1.  Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Authors:  Amit Dipak Amin; Soumya S Rajan; Winnie S Liang; Praechompoo Pongtornpipat; Matthew J Groysman; Edgar O Tapia; Tara L Peters; Lori Cuyugan; Jonathan Adkins; Lisa M Rimsza; Yves A Lussier; Soham D Puvvada; Jonathan H Schatz
Journal:  Cancer Res       Date:  2015-05-27       Impact factor: 12.701

Review 2.  A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer.

Authors:  Sulim Kang; Jaehyun Woo; Sungmin Kim
Journal:  Diagnostics (Basel)       Date:  2022-05-23

3.  ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Authors:  Jeffrey S Ross; Siraj M Ali; Omotayo Fasan; Jared Block; Sumanta Pal; Julia A Elvin; Alexa B Schrock; James Suh; Sahar Nozad; Sungeun Kim; Hwa Jeong Lee; Christine E Sheehan; David M Jones; Jo-Anne Vergilio; Shakti Ramkissoon; Eric Severson; Sugganth Daniel; David Fabrizio; Garrett Frampton; Vince A Miller; Philip J Stephens; Laurie M Gay
Journal:  Oncologist       Date:  2017-10-27

4.  Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population.

Authors:  Bojan Zaric; Vladimir Stojsic; Milana Panjkovic; Dragana Tegeltija; Vanesa Stepanov; Tomi Kovacevic; Tatjana Sarcev; Davorin Radosavljevic; Aleksandar Milovancev; Vasilis Adamidis; Paul Zarogoulidis; Wolfgang Hohenforst-Schmidt; Georgia Trakada; Aggeliki Rapti; Branislav Perin
Journal:  J Cancer       Date:  2016-10-25       Impact factor: 4.207

5.  Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Bing Liu; Maoxi Yuan; Yi Sun; Ziming Cheng; Zaiyong Zhang; Shizheng Hou; Xiangdong Wang; Jingfeng Liu
Journal:  Oncotarget       Date:  2017-12-16

6.  Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Wei Tian; Ping Zhang; Yuan Yuan; Xiao-Hui Deng; Rui Yue; Xiao-Zhu Ge
Journal:  J Clin Pharm Ther       Date:  2020-05-05       Impact factor: 2.512

7.  Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.

Authors:  Mathilde Couëtoux du Tertre; Maud Marques; Gerald Batist; Jason Agulnik; Suzan McNamara; Karen Gambaro; Cyrla Hoffert; Lise Tremblay; Nicole Bouchard; Razvan Diaconescu; Normand Blais; Christian Couture; Vincent Pelsser; Hangjun Wang; Laura McIntosh; Valérie Hindie; Stephane Parent; Laetitia Cortes; Yannick-André Breton; Gwenael Pottiez; Pascal Croteau; Valerie Higenell; Luisa Izzi; Alan Spatz; Victor Cohen
Journal:  Clin Proteomics       Date:  2020-02-07       Impact factor: 3.988

Review 8.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Authors:  Mingxiang Ye; Xinxin Zhang; Nan Li; Yong Zhang; Pengyu Jing; Ning Chang; Jianxiong Wu; Xinling Ren; Jian Zhang
Journal:  Oncotarget       Date:  2016-03-15

Review 9.  Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer.

Authors:  Jingjie Li; Zhi Yuan; Qun Wang; Weijie Fan; Guoping Zhang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.